One of our most important objectives in toxicologic pathology is the assessments of safety and of the possible risk to health of the many potential therapeutic agents as well as of inadvertent environmental hazards. The shortterm physiologic effects on the overall structure and functions of major organs, such as the central nervous, cardiovascular, pulmonary, and renal systems, are of course primary in the first tier in the sequence of assessments. These are reasonably straightforward in most instances and pose no major problems in their execution. Often they can be carried out without detailed knowledge in pathology.
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The next major area concerns the short-term and especially the long-term effects of levels of agents that do not induce a short-term adverse influence on organ anatomy and physiology. Of special importance in these areas is the possible induction of chronic disease, especially cancer. This occupies a considerable fraction of the activities in toxicologic pathology.
Our editor has recently introduced a division of labor in that we now have four areas of concentration in our participation in Toxicologic Pathology. This is a most welcome development. Three of these areas have as their major focus the modulations and improvements in our overall assessment of risk. A fourth area, Investigative Toxicologic Pathology, is somewhat more mechanistically oriented, especially at the subcellular biochemical-genetic levels. The focus in this commentary will be on ilpvplnnmpnt&dquo; In thi ~rp~ nz thpv rpl~tp tn ni-xxi potentially important approaches to the short-term assessments of risk and hazards to health.
The current acceptable assessment is a long-term costly undertaking that is not only expensive, but also very slow. Work in toxicologic pathology during the past several years has progressively concentrated on the development of reliable and valid monitors for assessments.
Increasingly we are seeing efforts to develop less costly and timelier ways to assess chronic toxicity, especially cancer, that are acceptable.
There are two major areas that stand out: genetic-genomic and phenotypic. The former are widely considered to be acceptable and highly relevant to cancer. The latter have only a small constituency in the population in toxicology-oncology, including ours.
There is a widespread feeling that structural gene changes, mutations and the like, are the basis for the development of cancer, including the many early changes that are regularly seen well before malignant neoplasia appears. Cancer is currently considered to be the result of a series or sequence of mutations, either present through inheritance or acquired during exposure to potential chemical, viral, and/or radiation-induced mutagenic agents in our environment. Based on this widely held speculation, several new and interesting approaches for short-term risk assessment have been proposed. These are based on the appearance of mutations in selected genes and/or the use of selected animals with very specific induced genetic changes, such as knock-out mice (e.g., p53) and transgenic animals (TG-AC) (5) .
An alternative view, outlined recently in an elegant fashion by Prehn (4) , proposes that cancer development is primarily an epigenetic process rather than mutational, and that the many mutations seen in virtually every cancer are mostly the result of cancer, not the cause. In other words, &dquo;cancers beget mutations&dquo; rather than &dquo;mutations beget cancers&dquo; (4) . This suggestion is based in part on the well known genomic instability in cancers (2) . If this overall suggestion has any validity, reliable short-term assessments for risk should use phenotypic rather than genotypic properties as end points.
I also tend to favor epigenetic rather than genetic approaches for the development of short-term tests. This is based on the hypothesis that cancer development with chemicals and other xenobiotics may consist of two quite different processes (1): (a) The first process, embodying the long period of development before unequivocal malignant neoplasia supervenes, is fundamentally a form of adaptation, termed &dquo;clonal adaptation,&dquo; which has striking survival value for the reacting organism (1, 3) , and bl is succeeded in a few lesions bv the real cancer-nro-ducing sequence. This begins with the first appearance of (1) . So far, virtually every gene proposed (p53, Rb, H-, K-and Nras, etc) has as a phenotypic product some basic disturbance in cell growth, either stimulatory or inhibitory. No real carcinogenic process that I know of in animals and humans, other than in vitro cell culture systems, has any disturbance in growth until very late in the process when malignant neoplasia appears. The growth control during the long period of carcinogensis has so far not been shown to be abnormal. Thus, no gene suggested to be involved in the long period of carcinogenesis has any phenotypic validation until late in the process. In this absence, why should we continue to focus on genes that have so far not been shown to play any role in the long carcinogenic process before cancer appears? All we find are associations, not causative factors. As emphasized by Medawar, Gould, and others, associations without mechanistic significance may well be irrelevant. We must have associations that can be validated phenotypically because cancer is clearly a broad spectrum of phenotypic changes with distinctive biological consequences.
If we are to develop short-term indices for cancer (or other chronic disease), we must concentrate on the assessment of the different phenotypic changes that characterize the process. Regrettably this is studied in very 'ew experimental or clinical instances. The most adianced is the rat liver (1). Here virtually every genotoxic carcinogen (approaching 100) induces a common pheiotypic pattern that forms the basis for an overall resisance of the new cells to cytotoxicity. There is increasing evidence that this cytotoxicity resistance can generate the nechanism for the next step, the promotion. This is by differential inhibition. Recently it has been shown that at least one nongenotoxic carcinogen, clofibrate, can also induce resistant hepatocytes that can be selected to generate nodules by differential inhibition. The development of valid short-term assessments for potential carcinogenicity is of vital importance to the future role of toxicologic pathology, both scientifically and especially in regulation. I think it behooves us to develop such short-term tests on the basis of solid science, rather than science fiction. This is a challenge we in toxicologic pathology must face up to if we are to continue to play our innovative role in a very important area in biology and medicine. EMMANUEL FARBER, M.D., PH.D.
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